Steven Mah
Stock Analyst at TD Cowen
(2.20)
# 2,722
Out of 4,749 analysts
32
Total ratings
40%
Success rate
9.7%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $52.37 | +10.75% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $27.31 | +13.53% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $13.36 | +798.20% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $7.24 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $25.08 | +67.50% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.17 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $3.22 | +210.56% | 1 | Feb 22, 2023 | |
| ME 23andMe Holding Co. | Initiates: Outperform | $120 | $3.10 | +3,770.97% | 1 | Sep 22, 2022 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.71 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $4.19 | +401.19% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $155 | $176.92 | -12.39% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $2.92 | +858.90% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $16.64 | +741.35% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.54 | +3,276.62% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $132.74 | +212.64% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.07 | +3,764.73% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $43.46 | +475.24% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $52.37
Upside: +10.75%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $27.31
Upside: +13.53%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $13.36
Upside: +798.20%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $7.24
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $25.08
Upside: +67.50%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.17
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $3.22
Upside: +210.56%
23andMe Holding Co.
Sep 22, 2022
Initiates: Outperform
Price Target: $120
Current: $3.10
Upside: +3,770.97%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.71
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $4.19
Upside: +401.19%
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $176.92
Upside: -12.39%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $2.92
Upside: +858.90%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $16.64
Upside: +741.35%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.54
Upside: +3,276.62%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $132.74
Upside: +212.64%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.07
Upside: +3,764.73%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $43.46
Upside: +475.24%